290 related articles for article (PubMed ID: 36507788)
1. Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada.
Skowronski DM; Kaweski SE; Irvine MA; Kim S; Chuang ESY; Sabaiduc S; Fraser M; Reyes RC; Henry B; Levett PN; Petric M; Krajden M; Sekirov I
CMAJ; 2022 Dec; 194(47):E1599-E1609. PubMed ID: 36507788
[TBL] [Abstract][Full Text] [Related]
2. Risk of hospital admission and death from first-ever SARS-CoV-2 infection by age group during the Delta and Omicron periods in British Columbia, Canada.
Skowronski DM; Kaweski SE; Irvine MA; Chuang ESY; Kim S; Sabaiduc S; Reyes RC; Henry B; Sekirov I; Smolina K
CMAJ; 2023 Oct; 195(42):E1427-E1439. PubMed ID: 37903524
[TBL] [Abstract][Full Text] [Related]
3. Age-Associated Seroprevalence of Coronavirus Antibodies: Population-Based Serosurveys in 2013 and 2020, British Columbia, Canada.
Tanunliong G; Liu AC; Kaweski S; Irvine M; Reyes RC; Purych D; Krajden M; Morshed M; Sekirov I; Gantt S; Skowronski DM; Jassem AN
Front Immunol; 2022; 13():836449. PubMed ID: 35401521
[TBL] [Abstract][Full Text] [Related]
4. Changing Patterns of SARS-CoV-2 Seroprevalence among Canadian Blood Donors during the Vaccine Era.
Reedman CN; Drews SJ; Yi QL; Pambrun C; O'Brien SF
Microbiol Spectr; 2022 Apr; 10(2):e0033922. PubMed ID: 35412385
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.
Tunheim G; Rø GØI; Chopra A; Aase A; Kran AB; Vaage JT; Lund-Johansen F; Hungnes O
Influenza Other Respir Viruses; 2022 Nov; 16(6):1004-1013. PubMed ID: 35770841
[TBL] [Abstract][Full Text] [Related]
6. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021.
Jones JM; Stone M; Sulaeman H; Fink RV; Dave H; Levy ME; Di Germanio C; Green V; Notari E; Saa P; Biggerstaff BJ; Strauss D; Kessler D; Vassallo R; Reik R; Rossmann S; Destree M; Nguyen KA; Sayers M; Lough C; Bougie DW; Ritter M; Latoni G; Weales B; Sime S; Gorlin J; Brown NE; Gould CV; Berney K; Benoit TJ; Miller MJ; Freeman D; Kartik D; Fry AM; Azziz-Baumgartner E; Hall AJ; MacNeil A; Gundlapalli AV; Basavaraju SV; Gerber SI; Patton ME; Custer B; Williamson P; Simmons G; Thornburg NJ; Kleinman S; Stramer SL; Opsomer J; Busch MP
JAMA; 2021 Oct; 326(14):1400-1409. PubMed ID: 34473201
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
Murhekar MV; Bhatnagar T; Selvaraju S; Saravanakumar V; Thangaraj JWV; Shah N; Kumar MS; Rade K; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Khan SMS; Kumar CPG; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Mohanty SS; Rangaraju C; Turuk A; Baradwaj DK; Chahal AS; Debnath F; Haq I; Kalliath A; Kanungo S; Kshatri JS; Lakshmi GGJN; Mitra A; Nirmala AR; Prasad GV; Qurieshi MA; Sahay S; Sangwan RK; Sekar K; Shukla VK; Singh PK; Singh P; Singh R; Varma DS; Viramgami A; Panda S; Reddy DCS; Bhargava B;
Lancet Glob Health; 2021 Mar; 9(3):e257-e266. PubMed ID: 33515512
[TBL] [Abstract][Full Text] [Related]
8. Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021.
Stringhini S; Zaballa ME; Pullen N; Perez-Saez J; de Mestral C; Loizeau AJ; Lamour J; Pennacchio F; Wisniak A; Dumont R; Baysson H; Richard V; Lorthe E; Semaani C; Balavoine JF; Pittet D; Vuilleumier N; Chappuis F; Kherad O; Azman AS; Posfay-Barbe K; Kaiser L; Guessous I;
Euro Surveill; 2021 Oct; 26(43):. PubMed ID: 34713799
[TBL] [Abstract][Full Text] [Related]
9. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020.
Bajema KL; Wiegand RE; Cuffe K; Patel SV; Iachan R; Lim T; Lee A; Moyse D; Havers FP; Harding L; Fry AM; Hall AJ; Martin K; Biel M; Deng Y; Meyer WA; Mathur M; Kyle T; Gundlapalli AV; Thornburg NJ; Petersen LR; Edens C
JAMA Intern Med; 2021 Apr; 181(4):450-460. PubMed ID: 33231628
[TBL] [Abstract][Full Text] [Related]
10. National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic.
Palmateer NE; Dickson E; Furrie E; Godber I; Goldberg DJ; Gousias P; Jarvis L; Mathie L; Mavin S; McMenamin J; McNeilly TN; Murcia P; Murray J; Reid G; Robertson C; Templeton K; von Wissmann B; Wallace LA; Waugh C; McAuley A
Public Health; 2021 Sep; 198():102-105. PubMed ID: 34411992
[TBL] [Abstract][Full Text] [Related]
11. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies.
Bergeri I; Whelan MG; Ware H; Subissi L; Nardone A; Lewis HC; Li Z; Ma X; Valenciano M; Cheng B; Al Ariqi L; Rashidian A; Okeibunor J; Azim T; Wijesinghe P; Le LV; Vaughan A; Pebody R; Vicari A; Yan T; Yanes-Lane M; Cao C; Clifton DA; Cheng MP; Papenburg J; Buckeridge D; Bobrovitz N; Arora RK; Van Kerkhove MD;
PLoS Med; 2022 Nov; 19(11):e1004107. PubMed ID: 36355774
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 cross-sectional seroprevalence study among public school staff in Metro Vancouver after the first Omicron wave in British Columbia, Canada.
Watts AW; Mâsse LC; Goldfarb DM; Irvine MA; Hutchison SM; Muttucomaroe L; Poon B; Barakauskas VE; O'Reilly C; Bosman E; Reicherz F; Coombs D; Pitblado M; O'Brien SF; Lavoie PM
BMJ Open; 2023 Jun; 13(6):e071228. PubMed ID: 37308276
[TBL] [Abstract][Full Text] [Related]
13. Population-Weighted Seroprevalence From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Vaccination, and Hybrid Immunity Among US Blood Donations From January to December 2021.
Busch MP; Stramer SL; Stone M; Yu EA; Grebe E; Notari E; Saa P; Ferg R; Manrique IM; Weil N; Fink RV; Levy ME; Green V; Cyrus S; Williamson PC; Haynes J; Groves J; Krysztof D; Custer B; Kleinman S; Biggerstaff BJ; Opsomer JD; Jones JM
Clin Infect Dis; 2022 Oct; 75(Suppl 2):S254-S263. PubMed ID: 35684973
[TBL] [Abstract][Full Text] [Related]
14. Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic.
Anand S; Montez-Rath M; Han J; Cadden L; Hunsader P; Kerschmann R; Beyer P; Boyd SD; Garcia P; Dittrich M; Block GA; Parsonnet J; Chertow GM
JAMA Netw Open; 2021 Jul; 4(7):e2116572. PubMed ID: 34251441
[TBL] [Abstract][Full Text] [Related]
15. Relative contribution of COVID-19 vaccination and SARS-CoV-2 infection to population-level seroprevalence of SARS-CoV-2 spike antibodies in a large integrated health system.
Chervo TC; Elkin EP; Nugent JR; Valice E; Amsden LB; Ergas IJ; Munneke JR; Flores M; Saelee GN; Hsiao CA; Schapiro JM; Quesenberry CP; Corley DA; Habel LA; Kushi LH; Skarbinski J
PLoS One; 2024; 19(6):e0303303. PubMed ID: 38900738
[TBL] [Abstract][Full Text] [Related]
16. Seropositivity of SARS-CoV-2 in an unvaccinated cohort in British Columbia, Canada: a cross-sectional survey with dried blood spot samples.
Racey CS; Booth A; Albert A; Smith LW; Krajden M; Murray MCM; Côté HCF; Gottschlich A; Goldfarb DM; Sadarangani M; Galea LAM; Kaida A; Brotto LA; Ogilvie GS
BMJ Open; 2022 Aug; 12(8):e062567. PubMed ID: 36038173
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 serology in pediatrics: Seroprevalence studies in unvaccinated children and humoral antibody response post vaccination.
Bohn MK; Steele S; Adeli K
Clin Biochem; 2023 Sep; 119():110630. PubMed ID: 37549823
[TBL] [Abstract][Full Text] [Related]
18. Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.
Boon SS; Wong MCS; Ng RWY; Leung DTM; Chen Z; Lai CKC; Ho WCS; Huang J; Wong BKC; Fung KSC; Chan PKS
JAMA Netw Open; 2021 Nov; 4(11):e2132923. PubMed ID: 34779848
[TBL] [Abstract][Full Text] [Related]
19. Riding high: seroprevalence of SARS-CoV-2 after 4 pandemic waves in Manitoba, Canada, April 2020-February 2022.
Duong S; Burtniak J; Gretchen A; Mai A; Klassen P; Wei Y; Loeppky C; Shaw SY; Bullard J; Van Caeseele P; Stein DR
BMC Public Health; 2023 Dec; 23(1):2420. PubMed ID: 38053033
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during the pre- and omicron-dominant wave, from January 2021 through December 2022, Thailand: A longitudinal study.
Suntronwong N; Vichaiwattana P; Klinfueng S; Puenpa J; Kanokudom S; Assawakosri S; Chansaenroj J; Srimuan D; Thatsanatorn T; Songtaisarana S; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
PLoS One; 2023; 18(4):e0279147. PubMed ID: 37104299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
